Get the Stockscreener App
1.45
1.05%
0.02
Erasca Inc stock is traded at $1.45, with a volume of 163.46K.
It is up +1.05% in the last 24 hours and up +1.76% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.43
Open:
$1.43
24h Volume:
163.46K
Relative Volume:
0.13
Market Cap:
$409.35M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.7683
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+2.12%
1M Performance:
+1.76%
6M Performance:
-9.12%
1Y Performance:
-40.04%
1-Day Range:
$1.4113
$1.4745
1-Week Range:
$1.34
$1.54
52-Week Range:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.445 | 424.93M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.34 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.49 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.20 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.01 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.05 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
When is the best time to exit Erasca Inc.Free Real Market Momentum Signal Generator - Newser
Brokerages Set Erasca, Inc. (NASDAQ:ERAS) PT at $4.57 - Defense World
What technical models suggest about Erasca Inc.’s comebackTrading Volume Anomaly Summary and Insight - Newser
Erasca Inc. stock momentum explainedIn-Depth Stock Trading Volume Analysis - Newser
Is it too late to sell Erasca Inc.Chart Driven Entry Timing for Swing Trades - Newser
How to build a dashboard for Erasca Inc. stockFree Weekly Top Gainers Forecast Watchlist - Newser
Can Erasca Inc. Rally Enough to Break EvenWeekly Chart Analysis With Entry Advice Provided - metal.it
Heatmap Data Shows High Activity in Erasca Inc. SectorLow Risk Swing Trade Opportunities Identified - metal.it
Multi factor analysis applied to Erasca Inc.Summary of Reliable Long-Term Trade Models - Newser
Erasca discloses new GTPase KRAS mutant inhibitors - BioWorld MedTech
Fibonacci Levels Suggest Recovery for Erasca Inc.Consistent Gain Investment Strategies Emerge - beatles.ru
Why is Erasca Inc. stock attracting strong analyst attentionFree Predictions - Jammu Links News
What analysts say about Erasca Inc. stockFastest-growing stock picks - Jammu Links News
Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors - MSN
Is it the right time to buy Erasca Inc. stockTap into rapid wealth building techniques - Jammu Links News
Is Erasca Inc. stock overvalued or undervaluedCapitalize on proven investment strategies - Jammu Links News
What catalysts could drive Erasca Inc. stock higher in 2025Massive portfolio appreciation - Jammu Links News
Published on: 2025-08-04 01:33:01 - Jammu Links News
When is Erasca Inc. stock expected to show significant growthGet professional guidance for market timing - Jammu Links News
How does Erasca Inc. compare to its industry peersDiscover market opportunities with expert help - Jammu Links News
What makes Erasca Inc. stock price move sharplyAchieve rapid portfolio growth with expert guidance - Jammu Links News
What is Erasca Inc. company’s growth strategyFree Daily Trading Room Entry - Jammu Links News
Is Erasca Inc. a growth stock or a value stockMaximize gains with data-driven stock picks - Jammu Links News
Predicting Erasca Inc. trend using moving averagesFree Daily Profit Focused Stock Screener - Newser
What institutional investors are buying Erasca Inc. stockGrow your portfolio with growth-oriented stocks - Jammu Links News
How does Erasca Inc. generate profit in a changing economyUnlock powerful stock screening tools - Jammu Links News
What are analysts’ price targets for Erasca Inc. in the next 12 monthsInvest smarter with data-backed insights - Jammu Links News
How to track smart money flows in Erasca Inc.Weekly Hot Stocks Based on Volume Flow - Newser
What are Erasca Inc. company’s key revenue driversPost Market Target Finder For Every Investor - Jammu Links News
Trend Reversal Possible in Erasca Inc. Charts IndicateStable Entry High Return Opportunities in Focus - metal.it
How many analysts rate Erasca Inc. as a “Buy”Financial News Planner For Beginners - Jammu Links News
Why Erasca Inc. stock attracts strong analyst attentionEntry and Exit Strategy Optimizer Tool Tested - metal.it
Is Erasca Inc. stock ready for a breakoutAI-Based Stock Behavior Forecast Engine - Newser
Can Erasca Inc. Overcome Bearish SentimentSecure Capital Picks With Upside Potential Tracked - beatles.ru
Machine Learning Models Forecast Erasca Inc. UptickPattern Breakout Entry Stock Forecast in Focus - beatles.ru
Can momentum traders help lift Erasca Inc.Long Term Stock Growth Plan Suggestions - Newser
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):